Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone sustained-release tablets for standardized cancer pain management
ChiCTR2600132626Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cancer pain comparing Oxycodone Hydrochloride Extended-Release Tablet Group with Hydromorphone Hydrochloride Sustained-Release Tablet Group (2 arms). Primary endpoint: Change from baseline in NRS pain score. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hydromorphoneoxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2600132626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132626.